PBM Reform 2026: What CAA, FTC, State Divestitures, and Transparency Rules Mean for Pharma Vendor Strategy

TL;DR

Thesis

PBM reform is already changing vendor strategy even before structural divestiture occurs. The base case is transparency, audit rights, rebate pass-through, net-cost cost sharing, and state-level any-willing-pharmacy pressure rather than an immediate federal breakup. That still weakens the economic logic that made PBM-owned specialty pharmacies and PBM-mediated copay maximizers unavoidable default partners. Manufacturers should plan around scenario probabilities, not wait for a single decisive statute or court ruling (FTC consent order; CAA 2026; KFF PBM reform overview; Arkansas Act 624 coverage).

The buyer thesis is to build optionality now: diversify SP networks, tighten hub and copay data rights, pre-negotiate any-willing-pharmacy and transition language, and run separate GTN forecasts for divestiture, transparency-only, and status-quo outcomes. Independent hubs and clinically specialized SPs benefit if structural steering weakens; market access and GTN vendors benefit regardless because every scenario increases contracting complexity.

The reform pressure stack

PBM reform is not one event. It is a stack of federal, state, judicial, and regulatory actions moving in parallel, often with conflicting timelines. Any serious vendor strategy starts by mapping the stack.

Federal actions

FTC second interim staff report (January 2025). The FTC’s second report on PBMs focused on specialty generics dispensed 2017-2022 through CVS Caremark, Express Scripts, and OptumRx. Key findings: PBM-affiliated pharmacies generated $7.3 billion in revenue above estimated acquisition costs, spread pricing produced $1.4 billion in profit, and markups on specialty generics reached three and four digits (tadalafil for pulmonary hypertension marked up 7,736% for commercial payers in 2022). The report documented steering of high-margin prescriptions to affiliated pharmacies and higher reimbursement at affiliated pharmacies than unaffiliated competitors on “nearly every specialty generic drug examined.”

FTC insulin administrative complaint (September 20, 2024). Filed against all three Big 3 PBMs and their GPOs (Zinc Health Services, Ascent Health Services, Emisar Pharma Services). Alleges the PBMs incentivized manufacturers to inflate list prices, restricted patient access to lower-list-price insulins, and shifted costs to vulnerable populations. The complaint triggered the February 4, 2026 Express Scripts consent order (see below). Cases against CVS Caremark and OptumRx remain pending.

FTC Express Scripts consent order (February 4, 2026). A 10-year order with a 3-year independent compliance monitor. Requires ESI to base member out-of-pocket costs on net drug cost rather than list price, stop preferring high-WAC drugs on standard formularies, and pass rebates directly to patients at the point of sale beginning 2028. FTC estimates approximately $7B in patient savings. ESI did not pay monetary penalties but agreed to structural changes that effectively rewrite its pharmacy-benefit operating model.

Consolidated Appropriations Act of 2026 (signed February 3, 2026). The first major federal PBM statute. Five substantive pillars:

1. PBMs classified as ERISA 408(b)(2) covered service providers: compensation disclosure obligations apply
2. 100% rebate pass-through to plan sponsors (rebates, fees, and other remuneration from pharma, aggregators, and GPOs)
3. Annual audit rights for plan sponsors using auditors of their choice
4. Semiannual reporting on steering, spread, and formulary economics
5. Prohibited-transaction consequences: a non-compliant PBM contract is “unreasonable” under ERISA, making the contract itself a prohibited transaction exposing plan fiduciaries to personal liability

Effective for plan years beginning on or after August 3, 2028 (January 1, 2029 for calendar-year plans). Expanded service-provider disclosure applies to contracts entered into, extended, or renewed after February 3, 2026.

PBM Price Transparency and Accountability Act (Wyden-Crapo, introduced December 4, 2025). Bipartisan Senate Finance Committee bill. Core provision: delink PBM compensation from drug prices in Medicare Part D. PBMs would earn flat service fees rather than rebate-based or spread-based compensation. Bans spread pricing in Medicaid and requires pass-through pricing for state Medicaid contracts. Nineteen bipartisan co-sponsors at introduction, the strongest political signal yet that delinking is the consensus federal end-state.

Break Up Big Medicine Act (Warren-Hawley, introduced February 10, 2026). Bans common ownership of insurer or PBM with provider or pharmacy/MSO operations. One-year divestiture timeline. Monthly 10% profit penalties for non-compliance. Bipartisan in sponsorship but lower probability of passage than the Wyden-Crapo transparency bill.

State actions

State	Action	Status	Key provisions
Arkansas	Act 624 (HB 1150)	Signed April 2025; preliminarily enjoined July 28, 2025	First state to ban PBM ownership of pharmacies; Commerce Clause and TRICARE preemption challenges succeeded in district court; state appealing
Iowa	SF 383	Signed June 11, 2025	100% rebate pass-through; NADAC + $10.68 dispensing fee; anti-steering; manufacturer-assistance inclusion in cost-sharing; pass-through pricing effective Jan 1, 2026
Louisiana	HB 358 and comprehensive PBM bill	Divestiture bill failed; broader reform passed 2025	Did not ban ownership; mandated disclosure, reimbursement floors; state awarded 2026 Medicaid PBM contract to Liviniti (non-integrated) instead of renewing CVS Caremark
California	Delinking law	2025	PBM compensation cannot be tied to drug price; flat-fee models required
Colorado	Delinking law	2025	Similar to California
26 states + DC/PR	Copay accumulator restrictions	In force	Affect ~16.8% of commercial market (~34.3M lives); only bind fully insured plans, not self-funded ERISA
All 50 states	Some form of PBM regulation	In force	Universal coverage; 270+ utilization management bills and 85+ pharmacy network bills filed in 2025 session

Louisiana is the most overlooked signal. The state did not pass structural separation, but its Medicaid PBM contract pivot to Liviniti (a Louisiana-based non-integrated PBM) represents a new lever: state procurement as PBM reform. The related Caremark settlement produced a $45M payment to Louisiana plaintiffs, a preview of the litigation exposure that will follow CAA’s audit-rights provisions into plan-sponsor suits.

Judicial and regulatory

• Gurwitch v. SaveOnSP (filed December 2024, ongoing): ERISA/RICO class action against Accredo, Express Scripts, and SaveOnSP alleging diversion of “hundreds of millions, if not billions” in manufacturer copay assistance
• FTC Caremark insulin case and FTC OptumRx insulin case: both pending; Express Scripts settlement is the template
• CMS-0057 (January 2027): FHIR-based electronic prior-authorization APIs; adjacent to PBM reform but reshapes PA workflows that hubs operate
• CMS IRA negotiation round 2 (2027 pricing): 15 additional drugs under Medicare Part D negotiation; intersects with PBM rebate economics

For the buyer-side vendor map behind that compliance wave, see CMS-0057 Vendor Readiness Matrix.

PBM-owned specialty pharmacy: what divestiture actually means

The Big 3 control approximately 68% of U.S. specialty prescription dispensing revenue through vertical integration:

• Cigna / Evernorth: Express Scripts (PBM) + Accredo (specialty pharmacy) + CuraScript SD (specialty distributor) + Shields Health Solutions stake ($3.5B, September 2025)
• CVS Health: Caremark (PBM) + CVS Specialty Pharmacy + Cordavis (private-label biosimilars) + Coram CVS Specialty Infusion Services (infusion)
• UnitedHealth / OptumRx: OptumRx (PBM) + OptumRx Specialty Pharmacy + Optum Frontier Therapies + Nuvaila (private-label biosimilars) + Genoa (behavioral)

Three divestiture outcomes to model

(1) Forced operational divestiture (Arkansas model, if upheld on appeal or replicated federally). Structural separation of PBM and SP. The PBM sets formulary and network; a legally independent SP competes for fills on merit. Revenue impact to the PBMs: loss of the ~25-30% EBITDA contribution that specialty dispensing currently provides within the combined Health Services segment. Revenue shift to PANTHERx Rare, Orsini, Onco360, Amber, Shields-enabled health-system specialty pharmacies, and other independent SPs.

(2) Limited-distribution restrictions. PBMs retain ownership but are prohibited from narrowing networks to affiliated pharmacies only. This is the any-willing-pharmacy model. Less dramatic than divestiture but structurally meaningful: manufacturers gain negotiating leverage, and LDD network design becomes a pure clinical-quality competition.

(3) Mandatory pass-through pricing with rebate transparency. The CAA 2026 / FTC consent order model. Preserves vertical integration but compresses PBM specialty-pharmacy margin through disgorgement, net-cost-based cost-sharing, and 100% rebate pass-through. The Big 3 replace the lost spread-pricing and rebate-retention revenue with private-label biosimilar programs (Cordavis, Quallent, Nuvaila) and clinical-service fees.

The base case through 2028 is (3), layered with state-level variants of (2). Scenario (1) becomes plausible only if Arkansas wins on appeal and 5+ additional states pass divestiture laws or the Break Up Big Medicine Act moves.

Impact on manufacturer SP contracting

If full divestiture happens (2027-2028 scenario). Limited distribution network (LDN) strategy must diversify rapidly. Today, Drug Channels tracked 382 LDD drugs as of January 2025, with PBM-affiliated pharmacies accessing ~50% of broadly-limited networks but only ~25% of exclusive networks. Independents like PANTHERx (12% of exclusive LDD) and McKesson Biologics (14%) already lead in rare-disease dispensing. Under divestiture, the remaining ~75% of volume currently captured by Big 3 SPs migrates. Winners: PANTHERx Rare (rare disease), Orsini (rare disease and gene therapy), Onco360 (oncology), Amber (rare and specialty), Shields Health Solutions (health-system model).

For the health-system side of that shift, use Health System SP Accelerators and Health System Specialty Pharmacy Build vs Buy.

If transparency-only outcome (CAA + FTC consent orders replicated). Manufacturer rebate vs discount architecture must be rebuilt. Rebate-based contracts that assume PBM retention of a share of rebates become ERISA-unreasonable by default. Manufacturers and plan sponsors will move toward net-price contracting, flat-fee PBM compensation, and bundled-service fee structures. GTN forecasts need to model:

• Net-cost-based member OOP: reduces the financial-toxicity abandonment effect that drives ~20-25% of hub enrollment volume today
• Rebate pass-through to patient at POS: alters the net-price signal payers use to negotiate
• Audit rights: plan sponsors will commission audits that surface contract anomalies. Expect increased claw-back risk

If status quo persists through 2026. This is the likely outcome for the near term, particularly because CAA provisions do not bind until plan years beginning August 2028 and the Arkansas injunction is in effect. Incremental risk management: diversify SP relationships even inside PBM-owned networks, pre-negotiate any-willing-pharmacy contingency language, and maintain manufacturer hub infrastructure as a hedge against future PBM copay-maximizer redesigns.

Impact on hub services

PBM reform hits hubs in two channels: copay-program integrity and pharmacy-coordination leverage.

Copay transparency reshapes routing

Today, copay programs are frequently PBM-mediated. PrudentRx (CVS), SaveOnSP (Express Scripts), and OptumRx accumulators reclassify targeted specialty drugs to inflate copays, drain manufacturer copay cards, and shift savings to plan sponsors rather than patients. The FTC Express Scripts consent order constrains these practices starting 2027-2028 by requiring net-cost-based cost-sharing.

When maximizer economics compress, manufacturer copay programs regain effectiveness. ConnectiveRx, AssistRx, CareMetx, and EVERSANA, all independent hubs without PBM ownership ties, are positioned to capture the re-centralized copay-administration workflow. See Hub Services Market Analysis for vendor tier detail.

Bundling leverage shifts

Historically, PBM-integrated hub programs (CVS CareTeam, Accredo patient services) could offer manufacturers a simplified bundle: hub + SP + formulary access. If any-willing-pharmacy provisions weaken PBM network narrowing, the bundle loses structural advantage. Hub selection becomes more merit-based: manufacturer priorities like speed-to-therapy, nurse quality, data transparency, and LDN flexibility rise above the “we own the channel” argument.

Distributor-owned hubs (Cencora Lash Group, McKesson CoverMyMeds, Cardinal Sonexus) face a subtler question: their leverage comes from distribution-to-pharmacy ties rather than PBM ties, so they are less exposed to PBM-reform specifically, but the broader vertical-integration scrutiny from the Break Up Big Medicine Act touches them too if it advances.

See Pharma Services Explained for a hub-versus-SP breakdown.

Impact on manufacturer GTN and access

Rebate disclosure changes payer negotiation

CAA 2026’s 100% rebate pass-through and semiannual reporting obligations mean plan sponsors will have visibility into rebate economics they never had. Expected second-order effects:

• Plan sponsors negotiate harder on net price. The rebate-retention game that financed PBM admin fees disappears. Plans either demand lower gross prices or lower admin fees, usually both.
• Employer-direct contracting grows. Transparent PBMs (Navitus, Capital Rx, Liviniti, and similar) gain share with mid-size and large self-funded employers. The Louisiana Medicaid pivot to Liviniti is a template.
• Manufacturer GTN becomes more forecastable in aggregate, less predictable per-plan. Overall rebate leakage should decline. But plan-by-plan architecture varies, so manufacturers must rebuild channel-economics models.

340B intersection

Many 340B contract pharmacies are PBM-owned specialty pharmacies. PBM-reform laws that restrict steering can interact with manufacturer 340B contract-pharmacy policies in unpredictable ways. The specific risk: if state any-willing-pharmacy laws force PBMs to accept 340B contract pharmacy arrangements they currently reject, 340B specialty dispensing volume could expand materially, and manufacturer 340B exposure grows. Track state-level ruling intersections; they are where the most surprises will come from.

Formulary placement dynamics

Delinking proposals (Wyden-Crapo) fundamentally change formulary construction incentives. If PBMs earn flat fees, the incentive to place higher-list-price drugs on preferred tiers disappears. The clinical-and-economic case for each drug must stand on its own. Manufacturers with genuinely differentiated products benefit. Manufacturers relying on rebate aggression to secure tier placement lose leverage. Trinity Life Sciences and peer market access consultancies see significantly elevated demand for formulary-strategy rework.

See Market Access Consulting for the consulting landscape.

Three scenarios and vendor strategies

Dimension	Scenario A: Full divestiture (2027-2028)	Scenario B: Transparency + disgorgement (base case)	Scenario C: Status quo muddle-through
Trigger	Arkansas win on appeal + federal Break Up Big Medicine	CAA 2026 + FTC replicates ESI terms on Caremark/OptumRx	Arkansas loss + CAA delayed or weakened in implementation
Big 3 SP share	Drops from 68% toward 40-50% by 2029	Stabilizes near 60-65% through 2028	Remains near 68%
Independent SP winners	PANTHERx, Orsini, Onco360, Amber, Shields capture materially	Modest share gains at margin, especially rare and oncology	Incremental only
Independent hub winners	ConnectiveRx, AssistRx, CareMetx, EVERSANA capture copay and routing workflow	Same winners, smaller magnitude	Status quo
Copay maximizers	Effectively banned via structural separation	Compressed via net-cost OOP requirements	Persist with state-by-state limitations
Private-label biosimilars	Cordavis, Quallent, Nuvaila face forced divestiture or formulary-leverage restriction	Continue, become primary PBM margin vehicle	Continue and expand
Market access consulting	Demand surge for structural re-contracting	Demand surge for audit-defensible contracting	Steady elevated demand
Manufacturer LDN design	Must rebuild around independents; 12-24 month transition cost	Incremental diversification from current baseline	Minimal change required
GTN forecast volatility	High in transition years, lower at new equilibrium	Moderate throughout	Low
Probability (2026-2028)	15-20%	55-60%	25-30%

Vendor-strategy implications

For specialty pharmacy contracts: Pre-negotiate scenario-based flexibility. Include any-willing-pharmacy contingency language. Diversify even in scenarios where PBM SPs retain share. Single-channel risk is now a regulatory-compliance risk, not just a concentration risk. Track top specialty pharmacies for pharma manufacturers for independent options by therapeutic area.

For hub services RFPs: Weight independence over bundling. The bundle premium PBM-integrated hubs commanded in 2020-2024 has a shortening half-life. Score vendors on data transparency, LDN flexibility, and copay-program integrity as first-order criteria.

For copay program architecture: Design for a post-maximizer world. Models built on the assumption that maximizers will continue draining manufacturer copay dollars are already obsolete for ESI and will be obsolete for Caremark and OptumRx within 24 months.

For GTN planning: Run Scenario A, B, and C models separately. The difference between Scenario A and Scenario C is 15-25 points of net-price realization for many specialty products. Most finance teams are still running single-point forecasts.

For market access consulting: This is a structural growth tailwind regardless of scenario. Complexity itself drives billable work. Trinity Life Sciences and peers have pipelines 18-24 months deep on CAA-readiness and FTC-consent-order response engagements.

Implications

Manufacturers should treat PBM reform as an active contracting constraint. New SP, hub, copay, and GTN agreements should include scenario language for divestiture, any-willing-pharmacy access, net-cost OOP requirements, rebate pass-through, audit-right requests, and plan-sponsor data disclosures. Contracts written as if 2024 PBM economics persist through 2029 will be hard to unwind.

Vendor scoring should increase weight on independence, data transparency, and transition capability. PBM-owned SPs may still be necessary for access, but they should not be the only operational path for specialty brands. Independent hubs and SPs should be developed as credible alternatives before regulation forces a rushed migration.

Procurement Triggers

Manufacturers should define trigger points that automatically reopen vendor strategy, rather than waiting for a full annual plan cycle:

Trigger	Vendor action
FTC settlement terms extend to Caremark or OptumRx	Re-run PBM-owned SP, copay-maximizer, and formulary-access assumptions for all affected brands.
Arkansas Act 624 injunction outcome changes	Activate any-willing-pharmacy and independent-SP contingency language; reassess state-by-state network access.
Plan sponsor requests CAA audit support	Pull GTN, rebate, data, PBM compensation, and specialty-pharmacy reporting vendors into a joint audit-response workflow.
PBM moves brand to private-label biosimilar or low-WAC alternative	Re-evaluate hub messaging, copay strategy, formulary defense, and patient-switch support.
State accumulator or delinking law becomes effective in a major market	Update copay adjudication rules, payer-policy content, and field / hub scripts.
Employer splits PBM from specialty pharmacy	Add independent and health-system SP options to LDD network modeling.

Trigger-based planning matters because PBM reform is staggered across courts, federal agencies, Congress, and state legislatures. A static 2026 vendor plan will be stale before the largest 2028-2029 effective dates arrive.

What to watch in 2026-2027

1. Arkansas Act 624 appeal outcome at the Eighth Circuit. A reversal revives structural-separation momentum nationally; an affirmance effectively kills the state-divestiture vector for 2-3 years.
2. FTC settlements with CVS Caremark and OptumRx. Timing and whether the terms match Express Scripts’ consent order. A weaker settlement for the remaining two signals enforcement fatigue; a stronger or faster settlement signals escalation.
3. Wyden-Crapo markup in Senate Finance. Delinking moving to committee markup with bipartisan sponsors would be the most important federal signal since CAA.
4. State legislative sessions 2026. At least 6 states are expected to introduce PBM pharmacy ownership bans in 2026 sessions. Early-stage bills to track: New York, Illinois, Minnesota, Michigan, Pennsylvania.
5. Gurwitch and copay-maximizer private litigation. If plaintiffs secure class certification and a damages award, it reshapes copay-maximizer economics faster than regulatory action.
6. Employer RFP patterns. Tyson Foods and Blue Shield of California dropped Caremark as PBM but retained CVS Specialty for dispensing. Whether this splits-the-stack pattern spreads to other Fortune 500 employers is the real-world test of whether vertical integration is commercially durable absent regulation.

The PBM ecosystem in April 2026 is at the most unstable moment in its 40-year history. Manufacturers that rebuild vendor strategy around scenario probability rather than single-point forecasts will own the transition. The ones that defer will inherit whatever architecture the FTC, Congress, and state legislatures happen to hand them.